N-terminal modified PEG-TRAIL
US9321825B2 · kind B2 · utility
1Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2007 |
| Grant date | Apr 26, 2016 |
| Priority date | — |
| Expiry date | Jan 20, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N30/96
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility and solution stability, with highly improved pharmacokinetic profiles. Thus, the PEG-TAIL conjugate may be very useful for preventing and treating proliferative diseases and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.